Sunshine Biopharma (SBFM) Non Operating Interest Expenses (2022)

Sunshine Biopharma (SBFM) posted Non Operating Interest Expenses of $217666.0 for Q3 2022, up 148.25% on a QoQ basis from $87680.0 in Q2 2022.

Sunshine Biopharma (SBFM) Non Operating Interest Expenses (2022) Analysis & Trends

Sunshine Biopharma's Non Operating Interest Expenses history runs 1 years deep, the most recent figure standing at $217666.0 for Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Interest Expenses (Qtr)
1	Haleon	89.28 Bn	87.42 Bn	-	-
2	Teva Pharmaceutical Industries	35.97 Bn	32.23 Bn	1.97 Bn	-
3	Zoetis	32.42 Bn	30.48 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	27.48 Bn	23.42 Bn	4.39 Bn	-
5	United Therapeutics	22.89 Bn	20.73 Bn	648.10 Mn	-
6	RedHill Biopharma	22.11 Bn	22.11 Bn	-	-
7	Viatris	20.44 Bn	18.64 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.76 Bn	16.44 Bn	800.70 Mn	-
9	Elanco Animal Health	12.62 Bn	12.19 Bn	785.00 Mn	-
10	Sunshine Biopharma	750,608.81	-6.16 Mn	2.18 Mn	-

Download Data